Grifols (GIKLY) Total Current Liabilities (2009 - 2025)
Grifols (GIKLY) posted Total Current Liabilities of $2.4 billion for Q4 2025, up 2.01% quarter-over-quarter from $2.3 billion in Q4 2024, and up 2.01% year-on-year from $2.3 billion in Q4 2024.
Grifols (GIKLY) Total Current Liabilities (2009 - 2025) Analysis & Trends
Grifols (GIKLY) has reported Total Current Liabilities for 16 consecutive years, with $2.4 billion the latest figure, recorded in Q4 2025.
- Total Current Liabilities for Q4 2025 came in at $2.4 billion, up 2.01% year-over-year; the trailing twelve-month figure through Dec 2025 was $2.4 billion (up 2.01% YoY), and the FY2025 annual result was $2.4 billion, up 4900.43% from the prior year.
- Total Current Liabilities was $2.4 billion for Q4 2025 at Grifols, up from $2.3 billion in the prior quarter.
- Over five years, Total Current Liabilities peaked at $4.0 billion in Q4 2021 and troughed at $2.1 billion in Q4 2022.
- Average Total Current Liabilities over 5 years is $2.6 billion, with a median of $2.4 billion recorded in 2025.
- Year-over-year, Total Current Liabilities jumped 149.68% in 2021 and tumbled 48.17% in 2022.
- Over 5 years, Total Current Liabilities stood at $4.0 billion in 2021, then sank by 48.17% to $2.1 billion in 2022, then rose by 21.45% to $2.5 billion in 2023, then slipped by 7.92% to $2.3 billion in 2024, then grew by 2.01% to $2.4 billion in 2025.
- Per Business Quant data, the three most recent Total Current Liabilities figures were $2.4 billion in Q4 2025, $2.3 billion in Q4 2024, and $2.5 billion in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 36.63 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 57.72 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 42.10 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -32.57 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 26.95 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 24.96 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 9.48 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 34.35 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Grifols | - | - | - | 2.35 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.35 Bn |
| Dec 31, 2024 | 2.30 Bn |
| Dec 31, 2023 | 2.50 Bn |
| Dec 31, 2022 | 2.06 Bn |
| Dec 31, 2021 | 3.97 Bn |
| Dec 31, 2020 | 1.59 Bn |
| Sep 30, 2020 | 1.45 Bn |
| Mar 31, 2020 | 1.47 Bn |
| Dec 31, 2019 | 1.51 Bn |
| Sep 30, 2019 | 1.55 Bn |
| Dec 31, 2018 | 1.44 Bn |
| Sep 30, 2018 | 1.26 Bn |
| Jun 30, 2018 | 1.21 Bn |
| Mar 31, 2018 | 1.49 Bn |
| Dec 31, 2017 | 1.15 Bn |
| Jun 30, 2017 | 989.95 Mn |
| Dec 31, 2016 | 1.16 Bn |
| Sep 30, 2016 | 1.03 Bn |
| Jun 30, 2016 | 1.10 Bn |
| Dec 31, 2015 | 1.15 Bn |